New Drug Combination for Previously Treated Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a new drug called lurbinectedin to paclitaxel (a standard chemotherapy) works better than paclitaxel alone for small cell lung cancer that has come back after prior treatment. The goal is to see if this combination helps patients live longer and controls their cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old
- You must have extensive-stage small cell lung cancer that was confirmed by a biopsy or tissue sample
- Your cancer must have grown back or gotten worse after receiving at least one prior platinum-based chemotherapy treatment
- You must be able to walk around and care for yourself (ECOG performance status 0–2)
- You must have at least one tumor that can be measured on imaging scans
- Your blood counts, kidney function, and liver function must be healthy enough (recent lab results within 2 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This Phase 2 study tests the combination of trilaciclib and lurbinectidin in adults whose cancer has already been treated, including with certain standard medicines. It aims to see if this combination can shrink tumors or slow cancer growth.
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new Carcinoma, Small Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.